Targeted Investigational Therapy Has Potential to Overcome Crizotinib Resistance in Lung Cancers
The investigational drug PF-06463922 may have the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results (Abstracts A277, PR10/B107, and C253) presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 19 to 23 in Boston.
Crizotinib Resistance a Major Challenge
About 3% to 5% of lung cancers harbor ALK mutations, and the U.S. Food and Drug Administration approved the ALK inhibitor crizotinib (Xalkori) in August 2011 for the treatment of patients who have these lung cancers. Although robust responses to crizotinib have been observed for lung cancers harboring ALK gene abnormalities, the majority eventually become resistant to the effects of the drug. In many cases, resistance arises because of genetic mutations in ALK.
“Resistance to targeted therapies such as crizotinib is a major challenge when treating patients with cancer,” said Tod Smeal, PhD, Associate Research Fellow in the Oncology Research Unit at Pfizer, Inc, in San Diego. “Our goal is to take advantage of everything we have learned about designing drugs that target kinases like ALK and the ways in which lung cancers become resistant to crizotinib to develop the best next-generation ALK inhibitor we can.
“Our preclinical studies suggest that we are making progress toward achieving our goal: PF-06463922 has potent ALK-inhibiting activity, it is capable of inhibiting all the crizotinib-resistant ALK mutants so far detected in patients, and it can efficiently access the brain. We are excited about these preclinical results and very hopeful that they will translate into meaningful responses in the clinic.”
Potent Brain-Penetrating ALK Inhibitor
After designing PF-06463922, Dr. Smeal and colleagues first showed in cell assays that it potently inhibited the activity of ALK and all eight of the mutant forms of ALK known to cause resistance to crizotinib in patients with lung cancer. They then showed that PF-06463922 inhibited the growth of tumors harboring three of the crizotinib-resistant ALK mutants, including the most resistant ALK mutant, G1202R, in mice.
Further analysis indicated that PF-06463922 readily entered the brains of mice, rats, and dogs. In mice, levels of PF-06463922 in the brain were 20% to 30% of levels of PF-06463922 in the blood. This is potentially clinically relevant because a significant number of lung cancer patients will develop brain metastasis during the course of their disease, according to Dr. Smeal. However, he noted that it will be important to see if these results in animals hold true in humans.
Dr. Smeal and colleagues also found that PF-06463922 potently inhibited the protein ROS1, a close relative of ALK recently implicated in a number of cancer types, including some lung and brain cancers. Further, the investigational agent had antitumor effects in two mouse models of cancers driven by ROS1 gene abnormalities, leading the researchers to suggest that PF-06463922 has potential as a treatment for this subgroup of cancers, in addition to its promise as a new treatment for ALK-driven cancers.
Dr. Smeal is an employee of Pfizer, Inc, which funded the study.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
